Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study - Summary - MDSpire
Advertisement
Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study
To evaluate the effectiveness and safety of benralizumab compared to two mepolizumab dosing strategies in patients with eosinophilic granulomatosis with polyangiitis (EGPA) over 24 months.
Key Findings:
Remission rates at 24 months were 73.7% for benralizumab, 81.0% for mepolizumab 300 mg, and 50.0% for mepolizumab 100 mg, with no significant differences reported.
GC-free status reached 63.2% with benralizumab, 85.7% with mepolizumab 300 mg, and 58.3% with mepolizumab 100 mg at 24 months, with no significant between-group differences.
Eosinophil counts decreased significantly, with near-complete suppression in the benralizumab group, indicating a strong therapeutic effect.
Pulmonary function improved, particularly in the benralizumab group, suggesting enhanced respiratory outcomes.
Adverse events were uncommon, with no serious events reported, indicating a favorable safety profile.
Interpretation:
The study indicates that anti–IL-5/IL-5R biologics are effective and well tolerated in EGPA, with a significant glucocorticoid-sparing effect, which may influence treatment strategies.
Limitations:
The observational design may introduce confounding by indication, potentially biasing the effectiveness results.
Comparative effectiveness conclusions are limited due to the study's design, which may not account for all variables influencing treatment outcomes.
Conclusion:
Findings support individualized biologic selection in EGPA, highlighting the effectiveness of both benralizumab and mepolizumab dosing strategies.
by Marta Codirenzi, Federica Davanzo, Luca Iorio, Eleonora Fiorin, Gabriella Guarnieri, Fulvia Chieco Bianchi, Alessia Achille, Maria Rita Marchi, Andrea Vianello, Andrea Doria, Roberta Ramonda, Roberto Padoan
